There is no evidence that DHEA  improves quality of life but there is some evidence that it is associated with and rogenic side effects .
There is uncertainty whether DHEA decreases menopausal symptoms , but DHEA may slightly improve sexual function compared with placebo
BACKGROUND During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels .
This can lead to the development of various perimenopausal and postmenopausal symptoms ( for example hot flushes , night sweats , vaginal dryness ) .
Dehydroepi and rosterone ( DHEA ) is one of the main precursors of and rogens , which in turn are converted to testosterone and estrogens .
It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri- and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function ( for example libido , dyspareunia , satisfaction ) .
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety .
This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of r and omised controlled trials .
OBJECTIVES To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal phase .
Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women.
OBJECTIVE To demonstrate bioavailability of 3 weeks of oral micronized DHEA and to delineate changes induced on insulin sensitivity , morphometric indexes , and lipoprotein profiles . DESIGN Oral micronized DHEa ( 50 mg/d ) was administered in 3-week treatments to 11 postmenopausal women in a prospect i ve , placebo-controlled , r and omized , blinded , crossover trial with an interarm washout . After dose ( 23 hour ) serum DHEA , DHEAS , T , and cortisol levels were measured , as were fasting lipoproteins , oral glucose tolerance tests ( OGTT ) , T-lymphocyte insulin binding and degradation , and urine collagen cross-links . Morphometric changes were determined by hydrostatic weighing . RESULTS Dehydroepi and rosterone sulfate , DHEA , T , and free T increased up to two times premenopausal levels with treatment . Fasting triglycerides declined ; no change in collagen cross-links or morphometric indexes was noted . Oral glucose tolerance test parameters did not change , but both T-lymphocyte insulin binding and degradation increased with DHEA . CONCLUSION Fifty milligrams per day of oral DHEA gives suprahysiologic and rogen levels ; 25 mg/d may be more appropriate . Dehydroepi and rosterone enhanced tissue insulin sensitivity and lowered serum triglycerides . Rationale is provided for postmenopausal replacement therapy with this and rogen
There is no evidence that DHEA  improves quality of life but there is some evidence that it is associated with and rogenic side effects .
There is uncertainty whether DHEA decreases menopausal symptoms , but DHEA may slightly improve sexual function compared with placebo
BACKGROUND During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels .
This can lead to the development of various perimenopausal and postmenopausal symptoms ( for example hot flushes , night sweats , vaginal dryness ) .
Dehydroepi and rosterone ( DHEA ) is one of the main precursors of and rogens , which in turn are converted to testosterone and estrogens .
It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri- and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function ( for example libido , dyspareunia , satisfaction ) .
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety .
This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of r and omised controlled trials .
OBJECTIVES To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal phase .